Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Hanmi Pharmaceutical confirms positive results for Tibumeshirnon and Keytruda in cancer trial Phase 2 trial highlights ...

Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the ...

China has become the second-largest developer of new drugs, behind only America. Read more at straitstimes.com.

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

Uterine cancer (also known as endometrial cancer) is the fourth most common cancer women in the U.S. are diagnosed with. It ...

Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...

Its firms are at the forefront of cheaper, faster drug discovery ...

Three mega-cap names recently announced billions in share repurchase authorizations. Mega-cap generally refers to stock with market capitalizations of $200 billion or more. Below, I’ll detail exactly ...

A groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...